81 related articles for article (PubMed ID: 22503974)
1. A novel antibody targeting the ligand binding domain of the thromboxane A₂ receptor exhibits antithrombotic properties in vivo.
Murad JP; Espinosa EV; Ting HJ; McClure D; Khasawneh FT
Biochem Biophys Res Commun; 2012 May; 421(3):456-61. PubMed ID: 22503974
[TBL] [Abstract][Full Text] [Related]
2. The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation.
Murad JP; Espinosa EV; Ting HJ; Khasawneh FT
Biochem Pharmacol; 2012 Jan; 83(1):88-96. PubMed ID: 22008592
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
4. Glybenclamide: an antidiabetic with in vivo antithrombotic activity.
Ting HJ; Khasawneh FT
Eur J Pharmacol; 2010 Dec; 649(1-3):249-54. PubMed ID: 20858477
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan.
Murad JP; Espinosa EV; Ting HJ; Khasawneh FT
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):308-14. PubMed ID: 22123197
[TBL] [Abstract][Full Text] [Related]
6. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Vilahur G; Casaní L; Badimon L
Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
8. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
9. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.
Grüner S; Prostredna M; Aktas B; Moers A; Schulte V; Krieg T; Offermanns S; Eckes B; Nieswandt B
Circulation; 2004 Nov; 110(18):2946-51. PubMed ID: 15505105
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
11. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
Stoll P; Bassler N; Hagemeyer CE; Eisenhardt SU; Chen YC; Schmidt R; Schwarz M; Ahrens I; Katagiri Y; Pannen B; Bode C; Peter K
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
13. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
14. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Herbert JM; Dol F; Bernat A; Falotico R; Lalé A; Savi P
Thromb Haemost; 1998 Sep; 80(3):512-8. PubMed ID: 9759636
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
16. [Terutroban and endothelial TP receptors in atherogenesis].
Verbeuren TJ
Med Sci (Paris); 2006 Apr; 22(4):437-43. PubMed ID: 16597416
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
18. Investigation of a Thromboxane A
Alshbool FZ; Karim ZA; Espinosa EVP; Lin OA; Khasawneh FT
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29936414
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.
Kim CW; Yun JW; Bae IH; Park YH; Jeong YS; Park JW; Chung JH; Park YH; Lim KM
Thromb Res; 2011 Jun; 127(6):565-70. PubMed ID: 21420150
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
